Studying the effect of Fexofenadine on patients with irritable bowel syndrome

Phase 3

Recruiting

• Conditions: Irritable bowel syndrome.; Irritable bowel syndrome

• Registration Number: IRCT20160813029327N20
• Lead Sponsor: Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with irritable bowel syndrome based on Rome IV criteria
Age between 18-65 years old
Informed consent

Exclusion Criteria

Patients with diabetes, cardiovascular diseases, neurological and psychiatric disorders, hepatic disorders, renal failure, Celiac and colitis
Pregnancy and lactation
History of drug allergy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Abdominal Pain (Severity of pain and Duration of pain). Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Abdominal distension (Bloating, Swollen or Tight tummy). Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Satisfaction with fecal excretion. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;The impact of the IBS on the Patient's Quality of Life. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Irritable Bowel Syndrome Severity Score. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).